Webinar
HER2-Positive Breast Cancer: Advances in Targeted Therapy
Date:
Fri 05 Apr, 2024 8:00–8:40pm
Duration:
40 mins
What the session is about
Discussion (8:00 to 8:30 pm)
- Definition
- Testing methods and interpretation of results
- Characteristics of Her2neu-positive breast cancer
- Her2neu directed targeted therapies and their mechanisms of action
- Management of Her2neu-positive breast cancer including neoadjuvant, adjuvant and palliative therapeutic options
Interactive Q&A (8:30 to 8:40 pm)
- Register now and send your questions through the chat window
- You can also send questions 'Live' during the Webinar on 5th April through the chat window below the video
About the presenter:
Dr. Mohit Saxena is a Senior Consultant in Medical Oncology at Marengo Asia Hospital, Gurgaon, Haryana
- He completed his DM (Medical Oncology) from Gujarat Cancer Research Institute, Ahmedabad & MD ( General Medicine) from Sawai Man Singh Medical College, Jaipur
- He ranked 1st in Rajasthan Pre-Medical Test in the year 2000
- He was a consultant in Medical Oncology at Narayana Superspeciality Hospital, Gurgaon, Haryana from August 2020 to October 2023
- He was a member of the organising committee for the 65th APICON 2010
- He was a faculty in the “Management of Cancer Thyroid: Paradigms & Challenges” in 2018
- Dr. Saxena's recently published article was on, ‘Treating low- and intermediate-risk acute promyelocytic leukaemia with and without chemotherapy: A comparison in a tertiary care centre’. Journal of Cancer Research and Therapeutics. 2023 April
- He was a principal investigator for A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-Center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
